Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment

The PI3K-Akt-mTOR pathway is a viable target for cancer treatment and can be used to treat various malignant tumours, including follicular lymphoma and breast cancer. Both enzymes, PI3K and mTOR, are critical in this pathway. Hence, in recent years, an array of inhibitors targeting these two targets...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2022-05, Vol.13, p.875372-875372
Main Authors: Wu, Xianbo, Xu, Yihua, Liang, Qi, Yang, Xinwei, Huang, Jianli, Wang, Jie, Zhang, Hong, Shi, Jianyou
Format: Article
Language:English
Subjects:
cancer treament
dual inhibitor
mTOR
Pharmacology
PI3K
PI3K-Akt-mTOR pathway
tumour
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The PI3K-Akt-mTOR pathway is a viable target for cancer treatment and can be used to treat various malignant tumours, including follicular lymphoma and breast cancer. Both enzymes, PI3K and mTOR, are critical in this pathway. Hence, in recent years, an array of inhibitors targeting these two targets have been studied, showing dual PI3K/mTOR inhibition compared with single targeting small molecule inhibitors. Inhibitors not only inhibit cell proliferation but also promote cell apoptosis. These inhibitors show high potency and little drug resistance even at low doses, suggesting that PI3K/mTOR inhibitors are promising cancer drugs. Herein, we summarised the recent research of PI3K/mTOR dual inhibitors-for example, structure-activity relationship, pharmacokinetics, and clinical practice, and briefly commented on them. https://clinicaltrials.gov.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2022.875372